NCT04332705Terminated
Cryptosporidium Infection and Human Colorectal Cancer
Role of the Protozoa Cryptosporidium in the Development of Colorectal Cancer in Humans
Source: ClinicalTrials.gov · Last updated 6 Nov 2026
Reason given: No other patients could be included within the time frame.
Brief summary (registry, in English)
It has been reported that Cryptosporidium parvum, a species of a protozoan frequently isolated from humans and animals, is able to induce digestive adenocarcinoma in a rodent model. Consistently, some epidemiological studies have reported an association with cryptosporidiosis in patients with colorectal adenocarcinoma. However, the correlation between cryptosporidiosis and human digestive cancer remains unclear at this time, and it is not known whether this intracellular parasite, considered an opportunistic agent, is able to induce gastrointestinal malignancies in humans. In order to add new arguments for a probable association between cryptosporidiosis and digestive human cancer, the main aim of this study is to determine prevalence and to identify species of Cryptosporidium among a French digestive cancer population.
- Status (registry)
- Terminated
- Study type
- Observational
- Enrollment
- 324117 (actual)
- First submitted
- 31 Mar 2020
- Start date
- 30 Jun 2020
- Primary completion date
- 6 Jun 2025
- Lead sponsor
- Lille Catholic University
- Diseases
- Colorectal cancer
- NCT number
- NCT04332705
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients undergoing pre-operative chemotherapy.
- Patients who have already had chemotherapy for less than one year or other immunosuppressive treatment
Who the study is looking for
- Cases:
- Age ≥ 18 years old
- Patients with colonic adenocarcinoma/intraepithelial neoplasia diagnosed prior to chemotherapy or radiotherapy who will undergo scheduled surgery. Patients with rectal cancer with indication for neoadjuvant treatment will still be included, but only biopsies used for diagnosis will be used
- Patient capable of receiving informed information
- Written informed consent
- Affiliation to a social security scheme
- Controls:
- Age ≥ 18 years old
- Patients with endoscopic indication for benign pathology
- Patients with indication for colectomy for benign pathology
- Patients with digestive cancer (stomach, oesophagus, biliary, pancreatic, etc.) of any type other than colorectal cancer before chemotherapy or radiotherapy
- Patient capable of receiving informed information
- Written informed consent
- Affiliation to a social security scheme
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Groupement des Hôpitaux de l'Institut Catholique de Lille | Lomme | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.